<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00168454</url>
  </required_header>
  <id_info>
    <org_study_id>191622-077</org_study_id>
    <nct_id>NCT00168454</nct_id>
  </id_info>
  <brief_title>A Research Study for Patients With Overactive Bladder</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether injections of botulinum toxin Type A into
      the bladder are safe and effective in treating overactive bladder.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Number of Urinary Urge Incontinence Episodes</measure>
    <time_frame>Baseline, Week 2, Week 6, Week 12</time_frame>
    <description>Mean number of urinary urge incontinence episodes measured over a 7-day diary prior to week 12. Urinary urge incontinence is defined as urinary leakage associated with a strong desire to urinate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Number of Micturitions</measure>
    <time_frame>Baseline, Week 2, Week 6, Week 12</time_frame>
    <description>Mean number of micturitions measured over a 7 day diary prior to each visit. Micturation is defined as urinating into the toilet.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Number of Nocturia Episodes</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Mean number of nocturia episodes measured over a 7 day diary prior to each visit. A nocturia episode is a void (urinating into the toilet) that interrupts one's sleep.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Cystometric Capacity (MCC) by Urodynamic Measurements</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Maximum Cystometric Capacity (maximum volume that the bladder can hold) measured in mean milliliters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incontinence Quality of Life Instrument (I-QOL)</measure>
    <time_frame>Baseline, Week 2, Week 6, Week 12</time_frame>
    <description>Measured on 3 domains; a 5-point scale (1-5) for each domain. Sum of the domain scores is normalized to a scale of 0-100 (100 = no impact of incontinence on daily activities, 0 = maximum impact of incontinence on daily activities). Mean scores presented.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">313</enrollment>
  <condition>Overactive Bladder</condition>
  <condition>Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (normal saline) injected into detrusor on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BOTOX 50 U</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>botulinum toxin Type A 50 U injected into detrusor on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BOTOX 100 U</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>botulinum toxin Type A 100 U injected into detrusor on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BOTOX 150 U</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>botulinum toxin Type A 150 U injected into detrusor on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BOTOX 200 U</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>botulinum toxin Type A 200 U injected into detrusor on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BOTOX 300 U</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>botulinum toxin Type A 300 U injected into detrusor on Day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>botulinum toxin Type A</intervention_name>
    <description>botulinum toxin Type A injected into detrusor on Day 1</description>
    <arm_group_label>BOTOX 50 U</arm_group_label>
    <arm_group_label>BOTOX 100 U</arm_group_label>
    <arm_group_label>BOTOX 150 U</arm_group_label>
    <arm_group_label>BOTOX 200 U</arm_group_label>
    <arm_group_label>BOTOX 300 U</arm_group_label>
    <other_name>BOTOXÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (normal saline) injected into detrusor on Day 1</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be between 18-85 years old

          -  Must have been diagnosed by his/her doctor with overactive bladder at least 6 months
             ago

          -  Must weigh at least 50 kg (110 lbs)

          -  Must be willing and able to record information regarding bladder function into a diary
             (provided)

          -  Must be willing and able to complete the entire course of the study

        Exclusion Criteria:

          -  Cannot currently be catheterizing as a way to control incontinence

          -  Must not have used botulinum toxin type A or any other botulinum toxin previously for
             any condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ghent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <results_first_submitted>September 2, 2009</results_first_submitted>
  <results_first_submitted_qc>January 15, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 11, 2010</results_first_posted>
  <last_update_submitted>October 11, 2013</last_update_submitted>
  <last_update_submitted_qc>October 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo (normal saline)injection on Day 1 into detrusor</description>
        </group>
        <group group_id="P2">
          <title>BOTOX 50 U</title>
          <description>botulinum toxin Type A 50 U injection on Day 1 into detrusor</description>
        </group>
        <group group_id="P3">
          <title>BOTOX 100 U</title>
          <description>botulinum toxin Type A 100 U injection on Day 1 into detrusor</description>
        </group>
        <group group_id="P4">
          <title>BOTOX 150 U</title>
          <description>botulinum toxin Type A 150 U injection on Day 1 into detrusor</description>
        </group>
        <group group_id="P5">
          <title>BOTOX 200 U</title>
          <description>botulinum toxin Type A 200 U injection on Day 1 into detrusor</description>
        </group>
        <group group_id="P6">
          <title>BOTOX 300 U</title>
          <description>botulinum toxin Type A 300 U injection on Day 1 into detrusor</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="57"/>
                <participants group_id="P3" count="54"/>
                <participants group_id="P4" count="49"/>
                <participants group_id="P5" count="53"/>
                <participants group_id="P6" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="48"/>
                <participants group_id="P4" count="40"/>
                <participants group_id="P5" count="47"/>
                <participants group_id="P6" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo (normal saline)injection on Day 1 into detrusor</description>
        </group>
        <group group_id="B2">
          <title>BOTOX 50 U</title>
          <description>botulinum toxin Type A 50 U injection on Day 1 into detrusor</description>
        </group>
        <group group_id="B3">
          <title>BOTOX 100 U</title>
          <description>botulinum toxin Type A 100 U injection on Day 1 into detrusor</description>
        </group>
        <group group_id="B4">
          <title>BOTOX 150 U</title>
          <description>botulinum toxin Type A 150 U injection on Day 1 into detrusor</description>
        </group>
        <group group_id="B5">
          <title>BOTOX 200 U</title>
          <description>botulinum toxin Type A 200 U injection on Day 1 into detrusor</description>
        </group>
        <group group_id="B6">
          <title>BOTOX 300 U</title>
          <description>botulinum toxin Type A 300 U injection on Day 1 into detrusor</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="44"/>
            <count group_id="B2" value="57"/>
            <count group_id="B3" value="54"/>
            <count group_id="B4" value="49"/>
            <count group_id="B5" value="53"/>
            <count group_id="B6" value="56"/>
            <count group_id="B7" value="313"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;45 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45-64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="21"/>
                    <measurement group_id="B6" value="29"/>
                    <measurement group_id="B7" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>65-74 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="15"/>
                    <measurement group_id="B7" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="47"/>
                    <measurement group_id="B5" value="46"/>
                    <measurement group_id="B6" value="52"/>
                    <measurement group_id="B7" value="288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Number of Urinary Urge Incontinence Episodes</title>
        <description>Mean number of urinary urge incontinence episodes measured over a 7-day diary prior to week 12. Urinary urge incontinence is defined as urinary leakage associated with a strong desire to urinate.</description>
        <time_frame>Baseline, Week 2, Week 6, Week 12</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo (normal saline)injection on Day 1 into detrusor</description>
          </group>
          <group group_id="O2">
            <title>BOTOX 50 U</title>
            <description>botulinum toxin Type A 50 U injection on Day 1 into detrusor</description>
          </group>
          <group group_id="O3">
            <title>BOTOX 100 U</title>
            <description>botulinum toxin Type A 100 U injection on Day 1 into detrusor</description>
          </group>
          <group group_id="O4">
            <title>BOTOX 150 U</title>
            <description>botulinum toxin Type A 150 U injection on Day 1 into detrusor</description>
          </group>
          <group group_id="O5">
            <title>BOTOX 200 U</title>
            <description>botulinum toxin Type A 200 U injection on Day 1 into detrusor</description>
          </group>
          <group group_id="O6">
            <title>BOTOX 300 U</title>
            <description>botulinum toxin Type A 300 U injection on Day 1 into detrusor</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Number of Urinary Urge Incontinence Episodes</title>
          <description>Mean number of urinary urge incontinence episodes measured over a 7-day diary prior to week 12. Urinary urge incontinence is defined as urinary leakage associated with a strong desire to urinate.</description>
          <population>Intent to Treat</population>
          <units>episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="49"/>
                <count group_id="O5" value="53"/>
                <count group_id="O6" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.5"/>
                    <measurement group_id="O2" value="30.3"/>
                    <measurement group_id="O3" value="27.8"/>
                    <measurement group_id="O4" value="28.3"/>
                    <measurement group_id="O5" value="24.1"/>
                    <measurement group_id="O6" value="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.3"/>
                    <measurement group_id="O2" value="-20.0"/>
                    <measurement group_id="O3" value="-18.6"/>
                    <measurement group_id="O4" value="-20.8"/>
                    <measurement group_id="O5" value="-16.8"/>
                    <measurement group_id="O6" value="-18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.2"/>
                    <measurement group_id="O2" value="-21.2"/>
                    <measurement group_id="O3" value="-19.9"/>
                    <measurement group_id="O4" value="-23.4"/>
                    <measurement group_id="O5" value="-20.0"/>
                    <measurement group_id="O6" value="-18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.4"/>
                    <measurement group_id="O2" value="-20.7"/>
                    <measurement group_id="O3" value="-18.4"/>
                    <measurement group_id="O4" value="-23.0"/>
                    <measurement group_id="O5" value="-19.6"/>
                    <measurement group_id="O6" value="-19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Number of Micturitions</title>
        <description>Mean number of micturitions measured over a 7 day diary prior to each visit. Micturation is defined as urinating into the toilet.</description>
        <time_frame>Baseline, Week 2, Week 6, Week 12</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo (normal saline)injection on Day 1 into detrusor</description>
          </group>
          <group group_id="O2">
            <title>BOTOX 50 U</title>
            <description>botulinum toxin Type A 50 U injection on Day 1 into detrusor</description>
          </group>
          <group group_id="O3">
            <title>BOTOX 100 U</title>
            <description>botulinum toxin Type A 100 U injection on Day 1 into detrusor</description>
          </group>
          <group group_id="O4">
            <title>BOTOX 150 U</title>
            <description>botulinum toxin Type A 150 U injection on Day 1 into detrusor</description>
          </group>
          <group group_id="O5">
            <title>BOTOX 200 U</title>
            <description>botulinum toxin Type A 200 U injection on Day 1 into detrusor</description>
          </group>
          <group group_id="O6">
            <title>BOTOX 300 U</title>
            <description>botulinum toxin Type A 300 U injection on Day 1 into detrusor</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Number of Micturitions</title>
          <description>Mean number of micturitions measured over a 7 day diary prior to each visit. Micturation is defined as urinating into the toilet.</description>
          <population>Intent to Treat</population>
          <units>micturitions</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="49"/>
                <count group_id="O5" value="53"/>
                <count group_id="O6" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.3"/>
                    <measurement group_id="O2" value="76.3"/>
                    <measurement group_id="O3" value="80.3"/>
                    <measurement group_id="O4" value="76.5"/>
                    <measurement group_id="O5" value="76.7"/>
                    <measurement group_id="O6" value="75.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.5"/>
                    <measurement group_id="O2" value="-10.0"/>
                    <measurement group_id="O3" value="-12.5"/>
                    <measurement group_id="O4" value="-9.8"/>
                    <measurement group_id="O5" value="-7.2"/>
                    <measurement group_id="O6" value="-9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.4"/>
                    <measurement group_id="O2" value="-15.2"/>
                    <measurement group_id="O3" value="-22.9"/>
                    <measurement group_id="O4" value="-17.0"/>
                    <measurement group_id="O5" value="-18.9"/>
                    <measurement group_id="O6" value="-19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.3"/>
                    <measurement group_id="O2" value="-15.3"/>
                    <measurement group_id="O3" value="-21.7"/>
                    <measurement group_id="O4" value="-18.8"/>
                    <measurement group_id="O5" value="-19.7"/>
                    <measurement group_id="O6" value="-21.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Number of Nocturia Episodes</title>
        <description>Mean number of nocturia episodes measured over a 7 day diary prior to each visit. A nocturia episode is a void (urinating into the toilet) that interrupts one's sleep.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo (normal saline)injection on Day 1 into detrusor</description>
          </group>
          <group group_id="O2">
            <title>BOTOX 50 U</title>
            <description>botulinum toxin Type A 50 U injection on Day 1 into detrusor</description>
          </group>
          <group group_id="O3">
            <title>BOTOX 100 U</title>
            <description>botulinum toxin Type A 100 U injection on Day 1 into detrusor</description>
          </group>
          <group group_id="O4">
            <title>BOTOX 150 U</title>
            <description>botulinum toxin Type A 150 U injection on Day 1 into detrusor</description>
          </group>
          <group group_id="O5">
            <title>BOTOX 200 U</title>
            <description>botulinum toxin Type A 200 U injection on Day 1 into detrusor</description>
          </group>
          <group group_id="O6">
            <title>BOTOX 300 U</title>
            <description>botulinum toxin Type A 300 U injection on Day 1 into detrusor</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Number of Nocturia Episodes</title>
          <description>Mean number of nocturia episodes measured over a 7 day diary prior to each visit. A nocturia episode is a void (urinating into the toilet) that interrupts one's sleep.</description>
          <population>Intent to Treat</population>
          <units>episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="49"/>
                <count group_id="O5" value="53"/>
                <count group_id="O6" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3"/>
                    <measurement group_id="O2" value="12.2"/>
                    <measurement group_id="O3" value="13.9"/>
                    <measurement group_id="O4" value="17.9"/>
                    <measurement group_id="O5" value="12.2"/>
                    <measurement group_id="O6" value="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3"/>
                    <measurement group_id="O2" value="-2.5"/>
                    <measurement group_id="O3" value="-4.1"/>
                    <measurement group_id="O4" value="-6.5"/>
                    <measurement group_id="O5" value="-3.8"/>
                    <measurement group_id="O6" value="-7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Cystometric Capacity (MCC) by Urodynamic Measurements</title>
        <description>Maximum Cystometric Capacity (maximum volume that the bladder can hold) measured in mean milliliters</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo (normal saline)injection on Day 1 into detrusor</description>
          </group>
          <group group_id="O2">
            <title>BOTOX 50 U</title>
            <description>botulinum toxin Type A 50 U injection on Day 1 into detrusor</description>
          </group>
          <group group_id="O3">
            <title>BOTOX 100 U</title>
            <description>botulinum toxin Type A 100 U injection on Day 1 into detrusor</description>
          </group>
          <group group_id="O4">
            <title>BOTOX 150 U</title>
            <description>botulinum toxin Type A 150 U injection on Day 1 into detrusor</description>
          </group>
          <group group_id="O5">
            <title>BOTOX 200 U</title>
            <description>botulinum toxin Type A 200 U injection on Day 1 into detrusor</description>
          </group>
          <group group_id="O6">
            <title>BOTOX 300 U</title>
            <description>botulinum toxin Type A 300 U injection on Day 1 into detrusor</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Cystometric Capacity (MCC) by Urodynamic Measurements</title>
          <description>Maximum Cystometric Capacity (maximum volume that the bladder can hold) measured in mean milliliters</description>
          <population>Intent to Treat</population>
          <units>milliliters</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="49"/>
                <count group_id="O5" value="53"/>
                <count group_id="O6" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="267.1"/>
                    <measurement group_id="O2" value="262.9"/>
                    <measurement group_id="O3" value="255.0"/>
                    <measurement group_id="O4" value="258.4"/>
                    <measurement group_id="O5" value="280.1"/>
                    <measurement group_id="O6" value="271.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.5"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="71.0"/>
                    <measurement group_id="O4" value="101.7"/>
                    <measurement group_id="O5" value="91.5"/>
                    <measurement group_id="O6" value="130.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incontinence Quality of Life Instrument (I-QOL)</title>
        <description>Measured on 3 domains; a 5-point scale (1-5) for each domain. Sum of the domain scores is normalized to a scale of 0-100 (100 = no impact of incontinence on daily activities, 0 = maximum impact of incontinence on daily activities). Mean scores presented.</description>
        <time_frame>Baseline, Week 2, Week 6, Week 12</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo (normal saline)injection on Day 1 into detrusor</description>
          </group>
          <group group_id="O2">
            <title>BOTOX 50 U</title>
            <description>botulinum toxin Type A 50 U injection on Day 1 into detrusor</description>
          </group>
          <group group_id="O3">
            <title>BOTOX 100 U</title>
            <description>botulinum toxin Type A 100 U injection on Day 1 into detrusor</description>
          </group>
          <group group_id="O4">
            <title>BOTOX 150 U</title>
            <description>botulinum toxin Type A 150 U injection on Day 1 into detrusor</description>
          </group>
          <group group_id="O5">
            <title>BOTOX 200 U</title>
            <description>botulinum toxin Type A 200 U injection on Day 1 into detrusor</description>
          </group>
          <group group_id="O6">
            <title>BOTOX 300 U</title>
            <description>botulinum toxin Type A 300 U injection on Day 1 into detrusor</description>
          </group>
        </group_list>
        <measure>
          <title>Incontinence Quality of Life Instrument (I-QOL)</title>
          <description>Measured on 3 domains; a 5-point scale (1-5) for each domain. Sum of the domain scores is normalized to a scale of 0-100 (100 = no impact of incontinence on daily activities, 0 = maximum impact of incontinence on daily activities). Mean scores presented.</description>
          <population>Intent to Treat</population>
          <units>Units on a scale</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="49"/>
                <count group_id="O5" value="53"/>
                <count group_id="O6" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.9"/>
                    <measurement group_id="O2" value="32.3"/>
                    <measurement group_id="O3" value="34.3"/>
                    <measurement group_id="O4" value="30.5"/>
                    <measurement group_id="O5" value="32.0"/>
                    <measurement group_id="O6" value="34.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8"/>
                    <measurement group_id="O2" value="21.1"/>
                    <measurement group_id="O3" value="28.1"/>
                    <measurement group_id="O4" value="29.5"/>
                    <measurement group_id="O5" value="26.7"/>
                    <measurement group_id="O6" value="31.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3"/>
                    <measurement group_id="O2" value="30.6"/>
                    <measurement group_id="O3" value="32.1"/>
                    <measurement group_id="O4" value="37.2"/>
                    <measurement group_id="O5" value="34.5"/>
                    <measurement group_id="O6" value="41.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.9"/>
                    <measurement group_id="O2" value="29.8"/>
                    <measurement group_id="O3" value="32.9"/>
                    <measurement group_id="O4" value="35.2"/>
                    <measurement group_id="O5" value="37.1"/>
                    <measurement group_id="O6" value="39.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Percentage of Patients With 100% Reduction From Baseline of Urinary Urge Incontinence Episodes</title>
        <description>Measured by the 7 day diary preceding each visit. Urinary urge incontinence is defined as urinary leakage associated with a strong desire to urinate.</description>
        <time_frame>Baseline, Week 2, Week 6, Week 12, Week 18, Week 24, Week 30, Week 36</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo (normal saline)injection on Day 1 into detrusor</description>
          </group>
          <group group_id="O2">
            <title>BOTOX 50 U</title>
            <description>botulinum toxin Type A 50 U injection on Day 1 into detrusor</description>
          </group>
          <group group_id="O3">
            <title>BOTOX 100 U</title>
            <description>botulinum toxin Type A 100 U injection on Day 1 into detrusor</description>
          </group>
          <group group_id="O4">
            <title>BOTOX 150 U</title>
            <description>botulinum toxin Type A 150 U injection on Day 1 into detrusor</description>
          </group>
          <group group_id="O5">
            <title>BOTOX 200 U</title>
            <description>botulinum toxin Type A 200 U injection on Day 1 into detrusor</description>
          </group>
          <group group_id="O6">
            <title>BOTOX 300 U</title>
            <description>botulinum toxin Type A 300 U injection on Day 1 into detrusor</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With 100% Reduction From Baseline of Urinary Urge Incontinence Episodes</title>
          <description>Measured by the 7 day diary preceding each visit. Urinary urge incontinence is defined as urinary leakage associated with a strong desire to urinate.</description>
          <population>Intent to Treat</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="49"/>
                <count group_id="O5" value="53"/>
                <count group_id="O6" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4"/>
                    <measurement group_id="O2" value="12.3"/>
                    <measurement group_id="O3" value="27.8"/>
                    <measurement group_id="O4" value="26.5"/>
                    <measurement group_id="O5" value="28.3"/>
                    <measurement group_id="O6" value="44.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2"/>
                    <measurement group_id="O2" value="24.6"/>
                    <measurement group_id="O3" value="44.4"/>
                    <measurement group_id="O4" value="49.0"/>
                    <measurement group_id="O5" value="49.1"/>
                    <measurement group_id="O6" value="55.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9"/>
                    <measurement group_id="O2" value="29.8"/>
                    <measurement group_id="O3" value="37.0"/>
                    <measurement group_id="O4" value="40.8"/>
                    <measurement group_id="O5" value="50.9"/>
                    <measurement group_id="O6" value="57.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6"/>
                    <measurement group_id="O2" value="26.3"/>
                    <measurement group_id="O3" value="38.9"/>
                    <measurement group_id="O4" value="44.9"/>
                    <measurement group_id="O5" value="39.6"/>
                    <measurement group_id="O6" value="46.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6"/>
                    <measurement group_id="O2" value="28.1"/>
                    <measurement group_id="O3" value="27.8"/>
                    <measurement group_id="O4" value="42.9"/>
                    <measurement group_id="O5" value="54.7"/>
                    <measurement group_id="O6" value="53.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2"/>
                    <measurement group_id="O2" value="21.1"/>
                    <measurement group_id="O3" value="35.2"/>
                    <measurement group_id="O4" value="28.6"/>
                    <measurement group_id="O5" value="41.5"/>
                    <measurement group_id="O6" value="46.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4"/>
                    <measurement group_id="O2" value="15.8"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="36.7"/>
                    <measurement group_id="O5" value="32.1"/>
                    <measurement group_id="O6" value="42.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The Safety Population is defined as all randomized patients who received treatment and was used to analyze Serious Adverse Events and Adverse Events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo (normal saline)injection on Day 1 into detrusor</description>
        </group>
        <group group_id="E2">
          <title>BOTOX 50 U</title>
          <description>botulinum toxin Type A 50 U injection on Day 1 into detrusor</description>
        </group>
        <group group_id="E3">
          <title>BOTOX 100 U</title>
          <description>botulinum toxin Type A 100 U injection on Day 1 into detrusor</description>
        </group>
        <group group_id="E4">
          <title>BOTOX 150 U</title>
          <description>botulinum toxin Type A 150 U injection on Day 1 into detrusor</description>
        </group>
        <group group_id="E5">
          <title>BOTOX 200 U</title>
          <description>botulinum toxin Type A 200 U injection on Day 1 into detrusor</description>
        </group>
        <group group_id="E6">
          <title>BOTOX 300 U</title>
          <description>botulinum toxin Type A 300 U injection on Day 1 into detrusor</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5"/>
                <counts group_id="E2" subjects_affected="9"/>
                <counts group_id="E3" subjects_affected="5"/>
                <counts group_id="E4" subjects_affected="7"/>
                <counts group_id="E5" subjects_affected="4"/>
                <counts group_id="E6" subjects_affected="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Bacterial pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Herpes ophthalmic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Skeletal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hip Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Polymyalgia rheumatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Osteoporotic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Squamos cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Normal pressure hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Schizophrenia, undifferentiated type</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cystitis noninfective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33"/>
                <counts group_id="E2" subjects_affected="44"/>
                <counts group_id="E3" subjects_affected="44"/>
                <counts group_id="E4" subjects_affected="39"/>
                <counts group_id="E5" subjects_affected="44"/>
                <counts group_id="E6" subjects_affected="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>White blood cells urine positive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Residual urine volume</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Bladder pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>Allergan, Inc.</organization>
      <phone>(714)246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

